Exenatide and the treatment of patients with Parkinson’s disease
2013 · Journal of Clinical Investigation · 494 citations
https://doi.org/10.1172/jci68295
A
Atbin Djamshidian
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
155
Papers
4.6K
Citations
36
h-index
80
i10-index
Atbin Djamshidian is an academic researcher from Innsbruck Medical University. The author has contributed to research in topics: Parkinson's Disease Mechanisms and Treatments & Neurological disorders and treatments & Obsessive-Compulsive Spectrum Disorders. The author has an h-index of 36, co-authored 132 publications.
ORCID: 0000-0001-7174-6000Papers by this author
worksMotor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
2014 · Journal of Parkinson s Disease · 292 citations
https://doi.org/10.3233/jpd-140364
Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations
2019 · CNS Drugs · 173 citations
https://doi.org/10.1007/s40263-019-00661-z
Stroop test performance in impulsive and non impulsive patients with Parkinson’s disease
2011 · Parkinsonism & Related Disorders · 83 citations
https://doi.org/10.1016/j.parkreldis.2010.12.014
Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study
2021 · Journal of Parkinson s Disease · 56 citations
https://doi.org/10.3233/jpd-212594
Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study
2021 · Journal of Parkinson s Disease · 56 citations
https://doi.org/10.3233/jpd-212594
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat